Your email has been successfully added to our mailing list.

×
0 0 -0.00727994705493058 -0.00727994705493058 -0.013015662916391 0.0180895654092213 0.00742701669240379 0.014780498566071
Stock impact report

J&J files U.S. application for MS med ponesimod [Seeking Alpha]

Johnson & Johnson (JNJ) 
Last johnson & johnson earnings: 4/14 06:31 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
Company Research Source: Seeking Alpha
Healthcare J&J files U.S. application for MS med ponesimod Mar. 18, 2020 4:06 PM ET | Johnson & Johnson (JNJ) Douglas W. House Johnson & Johnson (NYSE: marketing application MS is a chronic autoimmune inflammatory disorder of the central nervous system (CNS). Ponesimod modulates a protein called sphingosine-1-phosphate receptor 1 (S1P1) that reduces the number of circulating lymphocytes by trapping them in the lymph nodes which reduces the number of the pro-inflammatory cells that can cross into the CNS thereby dampening inflammation. Click to subscribe to real-time analytics on JNJ Now read: Johnson & Johnson Remicade Biosim Setback, And Other News: The Good, Bad And Ugly Of Biopharma » Show less Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for JNJ alerts
Opt-in for
JNJ alerts

from News Quantified
Opt-in for
JNJ alerts

from News Quantified